Enzymatic cytotoxins and their engineered chimeras: functions and applications in prostate carcinomas.

Starting date
January 1, 2001
Duration (months)
Managers or local contacts
Colombatti Marco
prostate cancer, immunotoxins, vaccines

Two different immunotherapy strategies will be evaluated in our research, one based on the use of anti-tumor Immunotoxins (ITs) (PASSIVE IMMUNOTHERAPY) and the second based on the use of genetically engineered cells (ACTIVE IMMUNOTHERAPY).
We expect that our efforts would enable us to set up in vitro and in vivo models to test separately and in combination the efficacy of these two treatment modalities, particularly for the management of bone metastases and of the minimal residual disease.


A.I.R.C. Associazione Italiana per la Ricerca sul Cancro
Funds: assigned and managed by the department

Project participants

Cristina Anselmi
Technical-administrative staff
Giuseppe Bellisola
Deborah Castelletti
Marco Colombatti
Fabrizio Comper
Giulio Fracasso
Technical-administrative staff


Research facilities